Sector Expert: Francois Brisebois

Laidlaw & Company

Subscribe to
Streetwise Reports

Companies Commented On

Recent Interviews

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story' (6/29/17)
beakers blacknblue630.jpg

Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs.

Recent Quotes

"On the back of DRRX's solid deal with Sandoz and with more catalysts to come in 2017 such as Posimir Phase 3 readout in 4Q17 and IND filings for DUR-928, we see potential near-term upside."

— Francois Brisebois, Laidlaw & Company (8/9/17)

"We donít believe DRRX could have asked for a better partner as Sandoz has a team of dedicated institutional sales professionals with significant presence in the hospital market."

— Francois Brisebois, Laidlaw & Company (5/11/17)

"We see the deal with DRRX and Sandoz AG as relatively heavily front loaded and are encouraged by this large pharma validation."

— Francois Brisebois, Laidlaw & Company (5/8/17)

Due to permission requirements, not all quotes are shown.